# Poolbeg Pharma major milestone, green light for POLB 001 trial to proceed

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-major-milestone-green-light-for-polb-001-trial-to-proceed/4121073623
- Published: 2022-07-20T07:07:46+01:00
- Author: Giles

**Poolbeg Pharma plc** ([LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a
unique capital light clinical model, announced today that it has received ethics
and competent authority approval to commence its Lipopolysaccharide (LPS) human 
challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator
which aims to address the unmet medical need for a treatment for severe influenza.

Key Highlights:

| • | Clinical trial activities will formally commence on 22 July 2022 | 
| • | The trial will assess the efficacy of POLB 001 in dampening the robust immune response to LPS which acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases | 
| • | Start of the trial demonstrates significant delivery on commitment at IPO | 
| • | Initial results expected in Q4 2022 at which point the Company intends to rapidly monetise by out-licensing / partnering with pharma and biotech companies for further development of POLB 001 | 
| • | Trial success would also pave the way for potential applications beyond severe influenza |

> **Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:** _“This is a major milestone
> for Poolbeg as we are ready to commence the LPS human challenge trial of POLB 
> 001, our severe influenza treatment. Significant preparatory work has been completed
> in order to reach this stage with the completion of GMP* manufacturing, formulation,
> trial protocol design amongst other vital regulatory requirements. We look forward
> to receiving the valuable, broad-ranging data and insights that this trial is 
> expected to generate by the end of 2022. We stated at our IPO in July 2021 that
> we intended to bring POLB 001 into the clinic for this LPS trial in the summer
> of 2022 and are happy to have achieved this stated objective and demonstrate our
> ability to effectively execute on our strategy._
> _“The unmet need for new treatments for severe influenza presents a significant
> opportunity to improve outcomes for patients as well as to potentially rapidly
> monetise our lead asset. The unique mode of action of POLB 001 to reduce hyperinflammatory
> response in the body means that it is agnostic to the strain of virus and has 
> the potential to expand to other disease indications and as such, could provide
> further opportunities to create significant value beyond severe influenza for 
> the Company and our shareholders.”_

*Good Manufacturing Practice

The information contained within this announcement is deemed by the Company to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No. 596/
2014 (as implemented into English law) (“MAR”). With the publication of this announcement
via a Regulatory Information Service, this inside information is now considered 
to be in the public domain.

Share on:
